Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Cumberland Pharmaceuticals News

    1,635 $ 0,00% +0,00 $
    In : 1,5232 € | 25.04.24 22:00:04 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0RC46
    ISIN: US2307701092
    US-Symbol: CPIX
    Typ: Aktie

    Cumberland Pharmaceuticals News

    02.04.24 - PR Newswire
    NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS
    NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS PR Newswire
    05.03.24 - PR Newswire
    Cumberland Pharmaceuticals Reports Annual 2023 Financial Results
    Cumberland Pharmaceuticals Reports Annual 2023 Financial Results PR Newswire
    27.02.24 - PR Newswire
    CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS
    CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS PR Newswire
    07.11.23 - PR Newswire
    Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results
    Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results PR Newswire
    31.10.23 - PR Newswire
    CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS
    CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS PR Newswire
    10.10.23 - PR Newswire
    NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE
    NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE PR Newswire
    08.08.23 - PR Newswire
    Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023
    Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023 PR Newswire
    01.08.23 - PR Newswire
    CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS
    CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS PR Newswire
    26.06.23 - PR Newswire
    NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS
    NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS PR Newswire
    23.05.23 - PR Newswire
    CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
    CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS PR Newswire
    15.05.23 - PR Newswire
    CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS
    CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS PR Newswire
    09.05.23 - PR Newswire
    Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update
    Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update PR Newswire
    02.05.23 - PR Newswire
    CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS
    CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS PR Newswire
    07.03.23 - PR Newswire
    CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022
    CUMBERLAND PHARMACEUTICALS REPORTS 17% REVENUE GROWTH FOR FULL YEAR 2022 PR Newswire
    28.02.23 - PR Newswire
    CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS
    CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS PR Newswire
    08.11.22 - PR Newswire
    Cumberland Pharmaceuticals Reports 41% Revenue Growth
    Cumberland Pharmaceuticals Reports 41% Revenue Growth PR Newswire
    01.11.22 - PR Newswire
    CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS
    CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2022 FINANCIAL RESULTS PR Newswire
    01.11.22 - PR Newswire
    CUMBERLAND PHARMACEUTICALS MOVES INTO NEW HEADQUARTERS AT BROADWEST
    CUMBERLAND PHARMACEUTICALS MOVES INTO NEW HEADQUARTERS AT BROADWEST PR Newswire
    09.08.22 - PR Newswire
    Cumberland Pharmaceuticals Reports 14% Revenue Growth
    Cumberland Pharmaceuticals Reports 14% Revenue Growth PR Newswire
    08.08.22 - PR Newswire
    CUMBERLAND PHARMACEUTICALS REPORTS 2.4M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2021
    CUMBERLAND PHARMACEUTICALS REPORTS 2.4M PATIENT DOSES DELIVERED, NO PRODUCT RECALLS, NO FDA ISSUES IN 2021 PR Newswire

    Newssuche

    Videos

    newspaper
    08:40 Uhr +24,14%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »